期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 25, 期 14, 页码 2804-2808出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2015.05.002
关键词
Alzheimer's disease; Drug discovery; BACE1; Indanone; AChE
资金
- PRIN [20103W4779]
- Unirimini S.p.A.
- CIRI (PORFESR project)
In recent years, a progressive increase in age-related disorders could be observed in most western countries, among which Alzheimer's disease (AD) is one of the most challenging. BACE1 could be seen as an attractive target to develop disease-modifying compounds, and in this context, a new series of hybrid molecules was designed and synthesized, based on a previously identified multitarget lead compound. In particular, the amino side chain was appropriately modified to fit BACE1 as additional target. In vitro testing results pointed out compound 8 (IC50 = 2.49 +/- 0.08 mu M), bearing the bulky bis(4-fluorophenyl)methyl)piperazine substituent, as the most potent BACE1 inhibitor of the series. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据